Details
In 2020, Illumina will be releasing a new version of its TruSight™ Oncology 500 assay, designed for use with circulating tumor DNA in liquid biopsy testing. In this webinar, taken from a live presentation given at AMP 2019, Dr. Biswajit Das of the Frederick National Laboratory (FNL)/MoCHA and Dr. Stephanie Hastings of Q2 Solutions discuss their validation studies. They share their observations regarding specificity and sensitivity of TruSight™ Oncology 500 ctDNA in detecting low level of variants in circulating tumor DNA, and its ability to assess multiple variant classes in a single assay. They also discuss their plans to incorporate TruSight™ Oncology 500 ctDNA into future clinical trials and research studies.
Analytical Validation of Illumina’s TSO500™ ctDNA pre-released version assay
Stepanie B. Hastings, PhD
Staff Scientist II in Assay Development
Translational Genomics at Q2 Solutions
TSO500™ ctDNA pre-released version: Pan-Cancer Liquid Biopsy Assay Platform for NCI Clinical Studies
Biswajit Das, PhD
Molecular Characterization Laboratory
Frederick National Laboratory of Cancer Research
Fill Out Form to Access Webinar
Your email address is never shared with third parties.
- Date & Time
- Nov 6, 2019
- 8:00 AM
- Location
- North America
- Affiliation
- Q2 and NCI
- Presenter
- Stephanie Hastings and Biswajit Das
- Topic
- Oncology, Cancer research